Journal of Clinical Oncology, Vol 19, Issue 2
(January), 2001: 322-328
© 2001 American Society for Clinical Oncology
Adjuvant Tamoxifen: Predictors of Use, Side Effects, and Discontinuation in Older Women
By Serkalem Demissie,
Rebecca A. Silliman,
Timothy L. Lash
From the Boston University School of Public Health, Boston University School of Medicine, and Boston Medical Center, Boston, MA.
Address reprint requests to Rebecca A. Silliman, MD, PhD, Boston Medical Center, 88 E Newton St, F4, Boston, MA 02118; email rsillima{at}bu.edu
PURPOSE: To identify predictors of adjuvant tamoxifen use, side effects, and discontinuation in older women.
PATIENTS AND METHODS: We followed a cohort of 303 women  55 years of age diagnosed with stage I or stage II breast cancer for nearly 3 years. Data were collected from women’s surgical records and from computer-assisted telephone interviews at 5, 21, and 33 months after primary tumor therapy.
RESULTS: Two hundred ninety-two (96%) of 303 patients in the study provided information about tamoxifen use. Tamoxifen use was reported by 189 patients (65%); 26 (15%) discontinued use during the follow-up period. Patients who were 65 to 74 years of age (relative to those 55 to 64 years of age), had stage II disease, were estrogen receptor–positive, saw a greater number of breast cancer physicians, and had better perceptions of their abilities to discuss treatment options with physicians had greater odds of tamoxifen use. Those who had better physical function, had received standard primary tumor therapy, and had obtained helpful breast cancer information from books or magazines had lesser odds of tamoxifen use. Patients 75 years of age (relative to those 55 to 64 years of age) and patients with better emotional health had significantly lesser odds of reporting side effects. Patients who were estrogen receptor–positive were less likely to stop taking tamoxifen; patients who experienced side effects were more likely to stop taking tamoxifen.
CONCLUSION: Deviations from a prescribed course of adjuvant tamoxifen occur relatively frequently. The clinical consequences of this deviation need to be identified.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
G. Kimmick, R. Anderson, F. Camacho, M. Bhosle, W. Hwang, and R. Balkrishnan
Adjuvant Hormonal Therapy Use Among Insured, Low-Income Women With Breast Cancer
J. Clin. Oncol.,
July 20, 2009;
27(21):
3445 - 3451.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Ziller, M. Kalder, U.-S. Albert, W. Holzhauer, M. Ziller, U. Wagner, and P. Hadji
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer
Ann. Onc.,
March 1, 2009;
20(3):
431 - 436.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Ruddy, E. Mayer, and A. Partridge
Patient adherence and persistence with oral anticancer treatment
CA Cancer J Clin,
January 1, 2009;
59(1):
56 - 66.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Magai, N. S. Consedine, B. A. Adjei, D. Hershman, and A. Neugut
Psychosocial Influences on Suboptimal Adjuvant Breast Cancer Treatment Adherence Among African American Women: Implications for Education and Intervention
Health Educ Behav,
December 1, 2008;
35(6):
835 - 854.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P Hadji
Menopausal symptoms and adjuvant therapy-associated adverse events
Endocr. Relat. Cancer,
March 1, 2008;
15(1):
73 - 90.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Owusu, D. S.M. Buist, T. S. Field, T. L. Lash, S. S. Thwin, A. M. Geiger, V. P. Quinn, F. Frost, M. Prout, M. U. Yood, et al.
Predictors of Tamoxifen Discontinuation Among Older Women With Estrogen Receptor-Positive Breast Cancer
J. Clin. Oncol.,
February 1, 2008;
26(4):
549 - 555.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Partridge, A. LaFountain, E. Mayer, B. S. Taylor, E. Winer, and A. Asnis-Alibozek
Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer
J. Clin. Oncol.,
February 1, 2008;
26(4):
556 - 562.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. L. Kahn
Moving Research From Bench to Bedside to Community: There Is Still More to Do
J. Clin. Oncol.,
February 1, 2008;
26(4):
523 - 526.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Clough-Gorr, P. A. Ganz, and R. A. Silliman
Older Breast Cancer Survivors: Factors Associated With Change in Emotional Well-Being
J. Clin. Oncol.,
April 10, 2007;
25(11):
1334 - 1340.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Perez
Appraising Adjuvant Aromatase Inhibitor Therapy
Oncologist,
November 1, 2006;
11(10):
1058 - 1069.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Fallowfield, L. Atkins, S. Catt, A. Cox, C. Coxon, C. Langridge, R. Morris, and M. Price
Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer
Ann. Onc.,
February 1, 2006;
17(2):
205 - 210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Fink, J. Gurwitz, W. Rakowski, E. Guadagnoli, and R. A. Silliman
Patient Beliefs and Tamoxifen Discontinuance in Older Women With Estrogen Receptor--Positive Breast Cancer
J. Clin. Oncol.,
August 15, 2004;
22(16):
3309 - 3315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. C Campbell, U. MacLeod, and D. Weller
Primary care oncology: essential if high quality cancer care is to be achieved for all
Fam. Pract.,
December 1, 2002;
19(6):
577 - 578.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Malin, M. A. Schuster, K. A. Kahn, and R. H. Brook
Quality of Breast Cancer Care: What Do We Know?
J. Clin. Oncol.,
November 1, 2002;
20(21):
4381 - 4393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Silliman, E. Guadagnoli, W. Rakowski, M. B. Landrum, T. L. Lash, R. Wolf, A. Fink, P. A. Ganz, J. Gurwitz, C. Borbas, et al.
Adjuvant Tamoxifen Prescription in Women 65 Years and Older With Primary Breast Cancer
J. Clin. Oncol.,
June 1, 2002;
20(11):
2680 - 2688.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
